SFA-005

N/A

Report date: 2024/11/08 15:30:20
NME

Base Information

Drug NameSFA-005
Drug Alias NameSFA-005
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFree fatty acid receptor 2 agonistsFree fatty acid receptor 3 agonists
TargetsFree fatty acid receptor 2Free fatty acid receptor 3
Therapy Area/IndicationsLiver NeoplasmsLeukemia, Myeloid, AcuteLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSFA Therapeutics IncTemple University
China Registration ClassN/A

Develop Information

Active CompaniesSFA Therapeutics IncTemple University
Inactive CompaniesN/A
Active IndicationsLiver NeoplasmsLeukemia, Myeloid, AcuteLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A